Abstract
In previous studies, it was shown that the overexpression of β2-adrenoceptor (β2AR) in the hearts of transgenic mice (Tg) leads to agonist-independent activation of adenylate cyclase and enhanced myocardial function. Here, we measured the physical coupling of β2AR and Gs by evaluating the coimmunoprecipitation of β2AR and Gs and the ligand binding properties of β2AR in the hearts of Tg mice to investigate the details of the interaction among ligand, receptor, and G protein. The following results were obtained: (i) coimmunoprecipitation of β2AR and Gs was increased in the absence of agonist in Tg mice compared with the control animals. This demonstrates directly the increased interaction between unliganded β2AR and Gs, which is consistent with increased background cAMP production and cardiac function in the hearts of Tg mice. (ii) Guanosine-5′-(β,γ-imido)triphosphate abolished the association of β2AR/Gs in the immunoprecipitate. (iii) The affinities for ligands that show agonist (isoproterenol, clenbuterol, and dobutamine), neutral antagonist (alprenolol and timolol), and negative antagonist (propranolol and ICI 118551) activities in this experimental system were increased, not changed and decreased, respectively, in Tg mice compared with the controls. (iv) This efficacy-dependent alteration in ligand affinities was still observed in the presence of a guanosine-5′-(β,γ-imido)triphosphate concentration that abolishes β2AR/Gscoupling. This suggests that the altered β2AR binding affinities in Tg mice are not due to the increased interaction between β2AR and Gs. These data cannot be explained by using ternary, quinternary, two-state extended ternary, or cubic ternary complex models. We therefore discuss the results using a “two-state polymerization model” that includes an isomerization step for the conversion of receptor between an inactive and an active form (denoted as R and R*, respectively) and a polymerization of the active state (R*n). The simplest form of this model (i.e., noncooperative dimerization of the receptor) is found to be consistent with the experimental data.
Footnotes
- Received October 23, 1996.
- Accepted May 5, 1997.
-
Send reprint requests to: Dr. H. Gürdal, AnkaraÜniversitesi Tip Fakültesi, Farmakoloji Ab.D., Sihhiye 06100, Ankara, Turkey. E-mail:gurdal{at}bilkent.edu.tr
-
This work is supported in part by Turkish Scientific and Technical Research Council Grants SBAG 1634 (H.G.) and SBAG AYD-98 (H.O.O. and H.G.); American Heart Association, Texas Affiliate, Grant 96R-458 (R.A.B.); Allegheny-Singer Research Institute; and American Heart Association, Southeastern Pennsylvania and Delaware Affiliates (M.D.J. and E.F.).
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
